All Title Author
Keywords Abstract

Cholesterol  2014 

Effects of Securigera securidaca Extract on Lipolysis and Adipogenesis in Diabetic Rats

DOI: 10.1155/2014/582106

Full-Text   Cite this paper   Add to My Lib


Diabetes mellitus is associated with dysregulation of adipose tissue metabolism and increased level of serum lipids. In our previous work we found that Securigera securidaca decreases cholesterol level in blood of diabetic rats. The present study was carried out to further investigate the effects of this plant on lipid metabolism, lipolysis, and adipogenesis, in diabetic rats. Female Wistar rats were rendered diabetic by intraperitoneal injection of streptozotocin. Retroperitoneal adipose tissue was removed from diabetic animals after seven days of streptozotocin injection. Effect of hydroalcoholic extract of S. securidaca seeds (100–800?μg/mL) on adipose tissue lipolysis was evaluated in ex vivo condition. Also, to evaluate adipogenesis, preadipocytes were isolated from adipose tissue and differentiated to adipocytes in the presence of the extract. The extract at concentration of 800?μg/mL decreased both basal and catecholamine-stimulated lipolysis . Incubation of differentiating preadipocytes with 800?μg/mL of S. securidaca extract decreased intracellular lipid droplet accumulation as evaluated with Oil Red O staining . The extract even at high concentrations had no effect on viability of preadipocytes. In conclusion, S. securidaca decreases lipolysis and adipogenesis without cytotoxicity, which makes it a good candidate for management of dyslipidemia and reduction of cardiovascular risks in diabetes. 1. Introduction Diabetes mellitus is a major cause of hospitalization and still is one of the main diseases causing death and disability. The number of diabetic patients is markedly increasing in the world. According to the World Health Organization reports (October, 2013), 347 million people suffer from diabetes worldwide and without urgent action, it will be the 7th cause of mortality in 2030. Diabetes is associated with impaired glucose and lipid metabolism and over time leads to microvascular and macrovascular complications such as cardiovascular diseases [1]. Dyslipidemia, a main risk factor of cardiovascular diseases, is often present in diabetic patients. Diabetic dyslipidemia is characterized by increased serum triglyceride and low density lipoprotein and decreased high density lipoprotein [2]. Patients with type-1 diabetes also undergo dysregulation of adipose tissue metabolism (lipolysis and lipogenesis) due to insulin deficiency. Currently, statins, fibrates, niacin, and bile acid binding sequestrants are the most widely used medications for dyslipidemia. However, the clinical uses of these drugs are accompanied with unpleasant side effects


[1]  A. D. Deshpande, M. Harris-Hayes, and M. Schootman, “Epidemiology of diabetes and diabetes-related complications,” Physical Therapy, vol. 88, no. 11, pp. 1254–1264, 2008.
[2]  M. Arca, G. Pigna, and C. Favoccia, “Mechanisms of diabetic dyslipidemia: relevance for atherogenesis,” Current Vascular Pharmacology, vol. 10, no. 6, pp. 684–686, 2012.
[3]  C. R. Harper and T. A. Jacobson, “Avoiding statin myopathy: understanding key drug interactions,” Clinical Lipidology, vol. 6, no. 6, pp. 665–674, 2011.
[4]  M. J. Sorrentino, “An update on statin alternatives and adjuncts,” Clinical Lipidology, vol. 7, no. 6, pp. 721–730, 2012.
[5]  M. P. Solano and R. B. Goldberg, “Management of dyslipidemia in diabetes,” Cardiology in Review, vol. 14, no. 3, pp. 125–135, 2006.
[6]  A. Ghorbani, “Phytotherapy for diabetic dyslipidemia: evidence from clinical trials,” Clinical Lipidology, vol. 8, no. 3, pp. 311–319, 2013.
[7]  A. Ghorbani, “Best herbs for managing diabetes: a review of clinical studies,” Brazilian Journal of Pharmaceutical Sciences, vol. 49, no. 3, pp. 413–422, 2013.
[8]  I. Ghiasi, M. R. Nikbakht, H. E. Sadeghi, V. Sabzali, S. Sabzali, and M. Shahrani, “The hypoglycemic effects of a hydro-alcoholic extract from Securigera securidaca seeds on induced diabetic in male rats,” Journal of Shahrekord University of Medical Sciences, vol. 8, pp. 68–73, 2007.
[9]  H. Hosseinzadeh, M. Ramezani, and A. R. Danaei, “Antihyperglycaemic effect and acute toxicity of Securigera Securidaca L. seed extracts in mice,” Phytotherapy Research, vol. 16, no. 8, pp. 745–747, 2002.
[10]  E. Porchezhian and S. H. Ansari, “Effect of Securigera securidaca on blood glucose levels of normal and alloxan-induced diabetic rats,” Pharmaceutical Biology, vol. 39, no. 1, pp. 62–64, 2001.
[11]  A. Garjani, F. Fathiazad, A. Zakheri et al., “The effect of total extract of Securigera securidaca L. seeds on serum lipid profiles, antioxidant status, and vascular function in hypercholesterolemic rats,” Journal of Ethnopharmacology, vol. 126, no. 3, pp. 525–532, 2009.
[12]  Z. Rajaei, M. R. Hadjzadeh, R. Moradi, A. Ghorbani, and A. Saghebi, “Antihyperglycemic and antihyperlipidemic effects of hydroalcoholic extract of Securigera securidaca seeds in streptozotocin-induced diabetic rats,” Advanced Biomedical Research. In press.
[13]  A. Ghorbani, G. R. Omrani, M. A. Hadjzadeh, and M. Varedi, “Proinsulin C-peptide inhibits lipolysis in diabetic rat adipose tissue through phosphodiestrase-3B enzyme,” Hormone and Metabolic Research, vol. 45, no. 3, pp. 221–225, 2013.
[14]  R. Shafiee-Nick, A. Ghorbani, F. Vafaee Bagheri, and H. Rakhshandeh, “Chronic administration of a combination of six herbs inhibits the progression of hyperglycemia and decreases serum lipids and aspartate amino transferase activity in diabetic rats,” Advances in Pharmacological Sciences, vol. 2012, Article ID 789796, 6 pages, 2012.
[15]  A. Ghorbani, G. R. Omrani, M. A. R. Hadjzadeh, and M. Varedi, “Effects of rat C-peptide-II on lipolysis and glucose consumption in cultured rat adipose tissue,” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 6, pp. 343–347, 2011.
[16]  A. Ghorbani and M. Abedinzade, “Comparison of in vitro and in situ methods for studying lipolysis,” ISRN Endocrinology, vol. 2013, Article ID 205385, 6 pages, 2013.
[17]  A. Ghorbani, M. R. Hadjzadeh, Z. Rajaei, and S. B. Zendehbad, “Effects of fenugreek seeds on adipogenesis and lipolysis in normal and diabetic rat,” Pakistan Journal of Biological Sciences, vol. 17, no. 4, pp. 523–528, 2014.
[18]  A. Ghorbani, S. A. Jalali, and M. Varedi, “Isolation of adipose tissue mesenchymal stem cells without tissue destruction: a non-enzymatic method,” Tissue & Cell, vol. 46, no. 1, pp. 54–58, 2014.
[19]  G. Yu, Z. E. Floyd, X. Wu et al., “Adipogenic differentiation of adipose-derived stem cells,” Methods in Molecular Biology, vol. 702, pp. 193–200, 2011.
[20]  S. M. Mortazavian, A. Ghorbani, and T. G. Hesari, “Effect of hydro-alcoholic extracts of viola tricolor and its fractions on proliferation of cervix carcinoma cells,” Iranian Journal of Obstetrics, Gynecology and Infertility, vol. 15, no. 22, pp. 9–16, 2012.
[21]  M. A. I. R. Hadjzadeh, J. Tavakol Afshari, A. Ghorbani, and M. T. Shakeri, “The effects of aqueous extract of garlic (Allium sativum L.) on laryngeal cancer cells (Hep-2) and L929 cells in vitro,” Journal of Medicinal Plants, vol. 5, no. 18, pp. 41–48, 2006.
[22]  P. Arner and D. Langin, “Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance,” Trends in Endocrinology and Metabolism, vol. 25, pp. 255–262, 2014.
[23]  E. Fabbrini, B. S. Mohammed, F. Magkos, K. M. Korenblat, B. W. Patterson, and S. Klein, “Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease,” Gastroenterology, vol. 134, no. 2, pp. 424–431, 2008.
[24]  M. Lafontan, “Adipose tissue and adipocyte dysregulation,” Diabetes & Metabolism, vol. 40, pp. 16–28, 2014.
[25]  O. Soehnlein and F. K. Swirski, “Hypercholesterolemia links hematopoiesis with atherosclerosis,” Trends in Endocrinology and Metabolism, vol. 24, no. 3, pp. 129–136, 2013.
[26]  E. A. Fisher and H. N. Ginsberg, “Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins,” The Journal of Biological Chemistry, vol. 277, no. 20, pp. 17377–17380, 2002.
[27]  S. H. Choi and H. N. Ginsberg, “Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance,” Trends in Endocrinology and Metabolism, vol. 22, no. 9, pp. 353–363, 2011.
[28]  V. Large, O. Peroni, D. Letexier, H. Ray, and M. Beylot, “Metabolism of lipids in human white adipocyte,” Diabetes & Metabolism, vol. 30, no. 4, pp. 294–309, 2004.
[29]  G. Perilli, C. Saraceni, MN. Daniels, and A. Ahmad, “Diabetic ketoacidosis: a review and update,” in Current Emergency and Hospital Medicine Reports, vol. 1, pp. 10–17, 1, 2013.
[30]  A. Ghorbani, M. Varedi, M. R. Hadjzadeh, and G. H. Omrani, “Type-1 diabetes induces depot-specific alterations in adipocyte diameter and mass of adipose tissues in the rat,” Experimental and Clinical Endocrinology and Diabetes, vol. 118, no. 7, pp. 442–448, 2010.


comments powered by Disqus